There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Bausch Health Companies Inc. (BHC) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.24, or -3.24%, to $7.16. The Bausch Health Companies Inc. has recorded 125,076 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
This NYSE-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $7.40 and fluctuated between $7.65 as its day high and $7.16 as its day low. The current market capitalization of Bausch Health Companies Inc. is $2.58B. A total of 5.28 million shares were traded on the day, compared to an average of 4.21M shares.
In the most recent transaction, Carson Seana sold 292 shares of BHC for 9.32 per share on Feb 28. After the transaction, the EVP, General Counsel now owns 359,185 company shares. In a previous transaction on Jun 01, Bausch Health Companies Inc. sold 4,550,357 shares at 17.05 per share. BHC shares that 10% Owner owns now total 310,449,643.
Among the insiders who sold shares, Bausch Health Companies Inc. disposed of 35,000,000 shares on May 10 at a per-share price of $17.05. This resulted in the 10% Owner holding 315,000,000 shares of BHC after the transaction.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BHC in the last 3 months, the mean price target is $8.75 with high estimates of $10.00 and low estimates of $7.00. In terms of 52-week highs and lows, BHC has a high of $19.04 and a low of $4.00.
As of this writing, BHC has an earnings estimate of $0.72 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $0.84 per share and a lower estimate of $0.63. The company reported an EPS of $0.76 in the last quarter, which was -9.50% lower than expectations of $0.84.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BHC’s latest balance sheet shows that the firm has $582.00M in Cash & Short Term Investments as of fiscal 2021. There were $22.65B in debt and $5.20B in liabilities at the time. Its Book Value Per Share was $-1.91, while its Total Shareholder’s Equity was $-34.00M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BHC is Overweight with a score of 3.14. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 5 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.